The Impact of Germline or Somatic HRD Testing on Treatment Decisions in Ovarian Cancer

Videos
Ali McBride, PharmD, MS, BCPS
Clinical Coordinator
The University of Arizona Cancer Center
Tucson, AZ
Paula Anastasia, RN, MN, AOCN
GYN Oncology Clinical Nurse Specialist
UCLA Health
Los Angeles, CA
Ali McBride, PharmD, and Paula Anastasia, RN, MN, AOCN, discuss how results from germline and somatic HRD testing help provide new options for patients with ovarian cancer. This approach has been a “game changer” in clinical outcomes for these patients.

Related Items


Subscribe to The Oncology Nurse-APN/PA

To sign up for our newsletter or print publications, enter your contact information below.

I'd like to receive: